Our study provides evidence that inhibiting CDK8 activity genetically or pharmacologically affects CRC growth, and when combined with IR treatment, it significantly augments IR sensitivity of CRC in vitro and in vivo. The gene discussed is CDK8; the disease is colorectal carcinoma.